Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults
Clinical Microbiology and Infection · 2026-01 · 32 (1) · 80-86
DOI: 10.1016/j.cmi.2025.08.032 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2026-01. Verfasst von Johannes Starp und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, LMU University Hospital, LMU Munich, Germany. Hauptthemen laut MEDLINE: Linezolid, Anti-Bacterial Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Else Kröner-Fresenius-Stiftung, European Society of Clinical Microbiology and Infectious Diseases, German Centre for Infection Research.
Abstract (Originalsprache)
OBJECTIVES: Linezolid is a frequently utilised antibiotic to treat serious infections caused by resistant pathogens in critically ill patients. Using the currently recommended one-dose-fits-all strategy leads to insufficient target attainment. Model-informed precision dosing (MIPD), an approach combining mathematical models and therapeutic drug monitoring (TDM), can improve target attainment. The underlying population pharmacokinetic model must be selected carefully. The aim of this study was to determine which models are applicable for MIPD in critically ill patients treated with intravenous linezolid. METHODS: Data for intravenous linezolid administration was obtained from three sites and 166 patients (498 TDM samples). The predictive performance of 30 published population pharmacokinetic models was analysed in three scenarios: considering patients' covariates only (a priori), and including one or two TDM samples (Bayesian forecasting, B1/B2). Metrics used for comparison were median relative prediction error (MDPE) (%), median absolute relative prediction error (MDAPE) (%), and the theoretical target attainment (%) for trough concentrations of 2 to 8 mg/L. RESULTS: The evaluated models were highly heterogeneous in model structure and predictive performance. MDPE, MDAPE and theoretical target attainment were improved by the inclusion of TDM samples. MDPE ranged from -135.9% to 110.9% (a priori), -21.1% to 69.7% (B1), and -15.6% to 54.6% (B2). Overall, the lowest MDAPE was demonstrated by the models of Boak, Fang, and Wu. Several models that resulted in similarly good results are also potentially useful for MIPD. DISCUSSION: Predictive performance varied substantially, underlining the importance of model evaluation prior to MIPD implementation for linezolid. Using the aforementioned models promises target attainment rates up to 80% in critically ill patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, LMU University Hospital, LMU Munich, Germany.
- Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Germany.
- Laboratory Dr Brunner, Laboratory Medical Care Center Konstanz GmbH, Constance, Germany.
- Institute of Laboratory Medicine, LMU University Hospital, LMU Munich, Germany.
- Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Germany.
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.
Förderung
- Else Kröner-Fresenius-Stiftung
- European Society of Clinical Microbiology and Infectious Diseases
- German Centre for Infection Research
- Joachim Herz Stiftung
- Pfizer
- Damp Stiftung
- Gilead Sciences
Zitieren
APA
Starp, J., Leonhardt, A., Zoller, M., Scharf, C., Zander, J., Paal, M., Greppmair, S., Schatz, L. M., Ermtraud, J., Kunzelmann, A. K., König, C., Grensemann, J., Reiter, L., Lau, C., Marriott, D., Stocker, S. L., Wicha, S. G., Liebchen, U., & PK/PD Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EPASG) (2026). Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults. Clinical Microbiology and Infection, 32(1), 80-86. https://doi.org/10.1016/j.cmi.2025.08.032
Vancouver
Starp J, Leonhardt A, Zoller M, Scharf C, Zander J, Paal M, et al. Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults. Clinical Microbiology and Infection. 2026;32(1):80-86. doi:10.1016/j.cmi.2025.08.032
BibTeX
@article{Starp2026,
author = {Starp, Johannes and Leonhardt, Antonia and Zoller, Michael and Scharf, Christina and Zander, Johannes and Paal, Michael and Greppmair, Sebastian and Schatz, Lea M and Ermtraud, Julian and Kunzelmann, Alexandra K and König, Christina and Grensemann, Jörn and Reiter, Lana and Lau, Cindy and Marriott, Deborah and Stocker, Sophie L and Wicha, Sebastian G and Liebchen, Uwe and PK/PD Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EPASG), PK/PD Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EPASG)},
title = {Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults},
journal = {Clinical Microbiology and Infection},
year = {2026},
volume = {32},
number = {1},
pages = {80--86},
doi = {10.1016/j.cmi.2025.08.032}
}
EUVIMED